Tardive dyskinesia: No clinically important improvement · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Mental state · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effects · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether withdrawal of anticholinergic medication changes acceptability of the treatment: leaving the study early compared with continuing anticholinergic medication (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any adverse effects · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether anticholinergic medication changes adverse effect: any adverse effects compared with other treatments (very low certainty).
1 finding from 1 review
Leaving the study early · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether anticholinergic medication changes acceptability of the treatment: leaving the study early compared with other treatments (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Mental state · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any adverse effects · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether anticholinergic medication changes tardive dyskinesia: Not improved to a clinically important extent compared with other treatments (very low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Mental state · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effects: Extrapyramidal effects ‐ concomitant anticholinergic medication ‐ short term (up to 12 weeks) Participants requiring concomitant anticholinergic medication · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ concomitant… compared with AMISULPRIDE (very low certainty).
1 finding from 1 review
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short/medium term Numbers requiring anticholinergic medication · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE showed no clear difference in adverse effects: general ‐ movement disorders ‐ requiring… compared with OTHER DEPOT ANTIPSYCHOTICS (low certainty).
1 finding from 1 review